Affiliations 

  • 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-Gu, Seoul, 06351, Korea
  • 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, 100142, China
  • 3 Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
  • 4 National Cheng Kung University Hospital, Tainan, Taiwan
  • 5 Department of Internal Medicine, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, South Korea
  • 6 Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
  • 7 Division of Hematology-Oncology, Kosin University Gospel Hospital, Busan, South Korea
  • 8 Oncocare Cancer Center, Tanglin, Singapore
  • 9 National Cancer Centre, Tanjong Pagar, Singapore
  • 10 Department of Haematology-Oncology, National University Health System, Queenstown, Singapore
  • 11 Indonesia Cipto Mangunkusumo National Central General Hospital, Central Jakarta, Indonesia
  • 12 Ruijin Hospital, Shanghai, China
  • 13 Division of Hematology and Oncology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University College of Medicine, Daegu, South Korea
  • 14 Department of Hematology-Oncology, Konkuk University Medical Center, Seoul, Korea
  • 15 Subang Jaya Medical Center, Kuala Lumpur, Malaysia
  • 16 Division of Hemato-Oncology, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
  • 17 Fudan University Shanghai Cancer Center, Shanghai, China
  • 18 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  • 19 Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
  • 20 Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, South Korea
  • 21 Division of Hematology and Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea
  • 22 Raffles Cancer Centre, 585 North Bridge Rd, Singapore
  • 23 Division of Hematology-Oncology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University, Chonju, South Korea
  • 24 Department of Hematology and Medical Oncology, College of Medicine, Kyung Hee University, Seoul, South Korea
  • 25 Division of Hematology-Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul, South Korea
  • 26 Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, South Korea
  • 27 Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, South Korea
  • 28 Department of Internal Medicine, Division of Hemato-Oncology, Kangdong Sacred Heart Hospital, Hallym University, Seoul, South Korea
  • 29 Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea
  • 30 Department of Internal Medicine, Soonchunhyang University College of Medicine, Puchon, South Korea
  • 31 Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea
  • 32 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 33 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, 100142, China. zhu-jun2017@outlook.com
  • 34 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-Gu, Seoul, 06351, Korea. wskimsmc@skku.edu
Int J Hematol, 2021 Sep;114(3):355-362.
PMID: 34302593 DOI: 10.1007/s12185-021-03179-7

Abstract

Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies have not yet been established for advanced CTCLs. In this study, relative incidence of CTCLs in Asia was estimated and the therapeutic outcomes presented based on various treatments currently used in clinics for advanced CTCLs. As part of a prospective registry study of peripheral T-cell lymphoma (PTCL) conducted across Asia, including Korea, China, Taiwan, Singapore, Malaysia, and Indonesia, subgroup analysis was performed for patients with CTCLs. Among 486 patients with PTCL, 37 with CTCL (7.6%) were identified between April 2016 and February 2019. Primary cutaneous ALK-negative anaplastic large cell lymphoma (ALCL, 35.1%) was the most common subtype. With a median follow-up period of 32.1 months, median progression-free survival (PFS) was 53.5 months (95% CI 0.0-122.5), and overall survival was not reached. 14 patients (48.2%) underwent subsequent treatment after the first relapse, but the response rate was 20% with a PFS of 2.2 months (95% CI 0.3-4.0). Six patients received autologous stem cell transplantation (auto-SCT). However, auto-SCT did not result in better outcomes. Additional studies are needed on standard care treatment of advanced or refractory and relapsed CTCLs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.